Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.




上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)


(Stock Code: 02196)

2015 THIRD QUARTERLY REPORT



B. F. B. B. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu


Chairman



As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Wang Pinliang, Ms. Kang Lan and Mr. John Changzheng Ma; and the independent non-executive directors of the Company are Dr. Zhang Weijiong, Mr. Cao Huimin, Mr. Jiang Xian and Dr. Wong Tin Yau Kelvin.

* for identification purposes only

1. IMPORTANT NOTICE



2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP



		7: 1	G LL : MB)
	As at the end of the Reporting Period (30 September 2015)	As at the end of the previous year (31 December 2014)	Change recorded at the end of the Reporting Period .1(e)-321red(th)2ber	
]
				-
]
]
]
				1
I .	1	I	I	I



Items	Amounts during the Reporting Period (Jul – Sep 2015)	Amounts from the beginning of the year to the end of the Reporting Period (Jan – Sep 2014)	Description
χ , χ	97,665,175.84	191,310,773.56	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			



1 1 1 1 1 1						73,142
The	shareholding s	tatus of the T	op 10 sharehold	lers		
	Shareholding		Number of	Shares pl	_	
	at the end of	Percentage	restricted _	locke		Capacity
Name of shareholders (full name)	the period	(%)	shares held	Status	Number	
HANGHAI F N HIGH CECHN L G (G) C MAN LIM ED ("F G.L.")	920,641,314	39.83	0	N ~	0	_ I,
HK CC N MINEE LIM ED (N 1)	402,619,300	17.42	0		0	7
CHINA EC I IE FINANCE C A I N LIMI ED	69,112,399	2.99	0	N	0	
NA I NAL CIAL EC F ND 104 F LI *	37,199,998	1.61	0	N	0	
H NG K NG EC I IE CLEA ING C MAAN LIMI ED (N _ 2)	33,556,005	1.45	0	N	0	
CEN ALH IJIN IN E MEN E D.	24,067,700	1.04	0	Ν	0	
INH A LIFE IN ANCE C ., L D. — DID IDEND — G DID IDEND — 018L — FH001 HANGHAI*	22,652,864	0.98	0	N	0	
ING CAA AL (BEIJING) C ., B D - ING CAA AL G / H F ND N . I*	17,695,247	0.77	0	N .	0	
F IC ING ELEGED 1*	16,764,537	0.73	0	Ν	0	
ING AN C D D — EL E INDE MEN ING CALLAL	16,567,783	0.72	0	N	0	

The shareholding status	•		han of shanes
	Number of unrestricted tradable	Type and num	ber of shares
Name of the shareholders	shares held	Type	Number
		Туре	
F i Gfi.	920,641,314	MB & & &	920,641,314
HK CC N MINEE LIM ED (Note 1)	402,619,300	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	402,619,300
CHINA EC I IE FINANCE C I A I N LIMI ED	69,112,399	MB x, £ £	69,112,399
NA I NAL CIAL EC F ND 104 F LI *	37,199,998	MB 1, √f	37,199,998
H NG K NG EC IE CLEA ING C MAN LIMI ED (Note 2)	33,556,005	MB ',	33,556,005
CEN AL H IJIN IN E MEN E D.	24,067,700	MB A A	24,067,700
INH A LIFE IN ANCE C ., IS D. — DID IDEND — G	22,652,864	MB I, I	22,652,864
HANGHAI* ING CAA AL (BEIJING) C ., IS D — A ING CAA AL G / H F ND N . I*	17,695,247	WB Y' T	17,695,247
FIC ING ELEC ED 1*	16,764,537	MB A A	16,764,537
ING AN C ., IS D — ELL E INDES MEN ING CALL AL	16,567,783	MB & L	16,567,783
	ING CAMAL (BG / HFNDN.I	EIJING) C B D — *, F IC ING EI — ELL E IN E MEN ING CAA AL (BE	ING CAA AL
D & I I I I I I I I I I I I I I I I I I	N 1 TI	1 1 1 1	

Note 1: HK CC N MINEE LIM ED, χ^{*} . H χ K χ^{*} $= 1 \int_{\Gamma} C_{\parallel} \int_{\Gamma} \chi C_{\parallel} \int_{\Gamma} N_{\parallel} \int_{\Gamma} C_{\parallel} \int_{\Gamma} V_{\parallel} \int_$

 $N = \mathbb{I} \setminus \mathbb{I}$


3. SIGNIFICANT EVENTS




		Balance Sl	heet	·
Items	Closing balance as at the end of the period	Opening balance as at the beginning of the year	Ratio of change	Reasons
I ▼ 1 ~ & & ~	485,549,599.95	198,755,576.52	144.29%	M 1 L L L L L L L L L L L L L L L L L L
A VIII.		990,340,787.62	-100.00%	(N ~)
_ X X	3,494,730.03	11,246,964.92	-68.93%	M I was to the second of the s
A. ************************************	3,529,897,004.62	2,499,156,438.67	41.24%	M. J.
D 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	167,214,321.23	89,379,481.02	87.08%	My to the second of the second
1 _m 1 ■	4,508,065,870.77	2,841,223,392.47	58.67%	Maria de la companya della companya
4.441	474,418,367.92	342,926,461.15	38.34%	M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
D'. '	14,831,357.70	1,279,819.25	1,058.86%	Maria Tarana Tar
		589,118,424.34	-100.00%	(N ~)
N -i Thank I I I	2,822,255,623.13	1,109,525,523.85	154.37%	Maria Caracter Control of the contro
7 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1	63,116,411.43	1,070,561,681.96	-94.10%	My Charles and Alpha Andrews
L i~ Im1	1,618,247,844.35	771,191,646.56	109.84%	Maria and a second a second and
B • • • • • • • • • • • • • • • • • • •	1,894,480,886.28	3,085,482,735.30	-38.60%	Marian In the mark that I have a second to the second to t

	Income Statement						
	Current amount	Amount of the last period					
Items	Jan - Sep 2015	Jan - Sep 2014	Ratio of change	Reasons			
F, ~~	339,686,256.62	251,024,209.33	35.32%				
A _ ¼m √m 1 ~	33,340,027.70	11,784,007.60	182.93%				
G Im I I I I	3,506,487.53	-9,516,778.44	136.85%	Marian Ma			
N / / / /	63,499,502.52	38,512,060.43	64.88%	M 1 L L L L L L L L L L L L L L L L L L			
N	10,862,409.73	15,531,263.99	-30.06%				
	-279,141,519.38	146,057,212.28	-291.12%	Maria A A A A A A A A A A A A A A A A A A A			

Statement of Cash Flow				
Current amount Amount of the last period				
Items	Jan - Sep 2015	Jan - Sep 2014	Ratio of change	Reasons
N L L L L L L L L L L L L L L L L L L L	1,161,951,526.99	843,637,595.71	37.73%	M I in a factor of the second
N L L L L L l lm	764,402,303.12	1,793,987,740.16	-57.39%	$\begin{array}{cccccccccccccccccccccccccccccccccccc$



				1 -		
						Whether
					Whether	timely and
					duration	
Background	Type	Covenantors	Undertakings	Validity period	specified	



Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

L : Chen Qiyu : Chen Qiyu : 29

APPENDICES

4.1 Financial statements

Consolidated balance sheet

30 September 2015



Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

	G & A: MB \\	1. 1.
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
C	3,516,813,404.78	3,695,698,185.82
- THE ALL		
L L L L L L L L L L L L L L L L L L L		
$E_{1,2,2,2,2,2}$ $\mathcal{L}_{1,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2$	38,724,495.54	33,770,584.14
B _M f z y T	408,527,911.80	472,523,132.71
La hay	1,789,464,377.02	1,504,149,790.72
	136,605,468.61	137,690,114.05
In Angel	677,257.70	1,023,889.42
$D_{r_1} = A_{r_1} \cdot A_{r_2}$	16,983,973.47	14,264,402.96
	485,549,599.95	198,755,576.52
A A STATE OF THE S		
I. L	1,627,321,198.79	1,604,562,390.25
A. A		990,340,787.62
N -1 A 2 12 12 2 2 2		
X + X	3,494,730.03	11,246,964.92
1.81	8,024,162,417.69	8,664,025,819.13
Non-current assets:		
Blow A a		
A	3,529,897,004.62	2,499,156,438.67
H		
L 1 - A A A A A A A A A A A A A A A A A A		
L 1- 1, 1, 1 ~ 10	13,489,435,775.47	11,905,750,117.54
	1 700 000 100 00	
F, Z	4,720,292,409.25	4,623,958,317.63
G A LA	964,172,888.14	1,051,988,109.53
Mr. L. K	3,233,982.94	5,450,698.63
At 1 in 1 th and		
- 1 T 1 T 1 T 1 T 1 T 1 T 1 T 1 T 1 T 1	2 957 217 020 41	2 922 492 002 20
D. W. J. J. J.	2,857,317,020.41	2,822,483,093.20 89,379,481.02
G	167,214,321.23	
<u>`</u>	3,292,538,591.11	3,255,041,739.55 13,583,440.85
L to H and L and I h	11,804,369.09	
D #	92,366,614.48	101,221,671.79
- 1 A - 1 A 1 A	262,125,551.28	304,238,328.42
- 1 A - 1 A - 1	29,390,398,528.02	26,672,251,436.83

Consolidated balance sheet (Continued)

30 September 2015

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:	01 010 1 0110 1	VI VIIV I VIII
1- 1 -	4,508,065,870.77	2,841,223,392.47
Bu III		
D. 1 1 2 2 2		
L X W W ZX		
F. A.	(7.000.505.70	
B _H T	67,928,606.53	70,987,451.05
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	874,465,599.33 226,002,022.22	833,974,948.21 266,518,255.34
G A.I.A.	220,002,022.22	200,318,233.34
E		
/ Inha- 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	296,895,628.48	298,472,746.11
	474,418,367.92	342,926,461.15
	166,803,873.32	177,075,081.31
Description	14,831,357.70	1,279,819.25
- L	1,379,103,280.44	1,935,656,885.83
23 1 2 2 2 1 2 2 2 p		
Tit. talk.		
A_{i} A_{i		
A_{i}^{m} , A_{i}^{m} , A_{i}^{m} , A_{i}^{m} , A_{i}^{m}		
Limber 18 10 10 10 10 10 10 10 10 10 10 10 10 10		589,118,424.34
N -1 M page 12 2 M A	2,822,255,623.13	1,109,525,523.85
7 × 1 × 1 × 1 × 1	63,116,411.43	1,070,561,681.96
No. of the last of	10,893,886,641.27	9,537,320,670.87
Non-current liabilities:	1,618,247,844.35	771 101 646 56
B ml	1,894,480,886.28	771,191,646.56 3,085,482,735.30
Lucat	890,883,419.71	710,056,624.65
The state of the s	070,003,417.71	710,030,024.03
A A Day to The Transfer of the		
D. A.	178,123,561.73	139,593,190.51
D. A. D. D. C.	1,934,427,964.42	1,929,331,107.42
The state of the s	73,391,869.13	60,299,392.99
-1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	6,589,555,545.62	6,695,954,697.43
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	17,483,442,186.89	16,233,275,368.30
Equity:		
1 - 1 - (2,311,380,364.00	2,311,611,364.00
C2, ADAD	6,049,708,237.59	6,123,454,191.14
L': X L		
	929 469 407 91	1 120 265 125 72
1	838,468,407.81 1,662,373,054.64	1,120,365,125.73 1,662,373,054.64
	1,002,373,034.04	1,002,575,054.04
	6,700,890,376.05	5,457,045,050.64
EAL A A L L	5,700,000,570.05	2, 127,012,020.04
	17,562,820,440.09	16,674,848,786.15
N - A A A A A A A A A A A A A A A A A A	2,368,298,318.73	2,428,153,101.51
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	19,931,118,758.82	19,103,001,887.66
	37,414,560,945.71	35,336,277,255.96

Legal Representative:

Chief Financial Officer:

Director of the Accounting Department:

Chen Qiyu

Guan Xiaohui

Yan Jia

Balance Sheet of the Parent Company (Continued)

30 September 2015

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
1-, 1 =	1,834,226,000.00	
F ALL		
But said		
T T T T		
	78,632,661.11	72,568,579.44
	23,932,653.33	21,842,286.49
I of the same	147,159,729.00	160,716,398.26
D ₁ , z	1,364,923.50	1,062,450.00
- A	453,068,674.16	587,606,051.26
N -1 A Danky La 1	2,641,935,028.99	1,037,216,423.85
- x 1 - X - X - X - X - X - X - X - X - X -		998,894,520.55
A Design of	5,180,319,670.09	2,879,906,709.85
Non-current liabilities:		
L 1= 4.1=	186,740,000.00	85,000,000.00
B r	1,894,480,886.28	3,085,482,735.30
L radius var		
A Az namny		
D. A.	1,525,000.00	1,750,000.00
D. A. — D—D. T	1,209,260,573.79	1,192,857,263.79
- L - L M 10-10-7		
-1 M (b=0b r'	3,292,006,460.07	4,365,089,999.09
the second of	8,472,326,130.16	7,244,996,708.94
Equity:		
1 -	2,311,380,364.00	2,311,611,364.00
C & &	8,227,835,906.44	8,270,816,715.22
L:1_1 _1		
- A 14 A - 1 - 1 - 1 - 1 - 1	55,747,958.04	224,689,817.57
1 & p & s & s & s & s & s & s & s & s & s	949,985,460.52	949,985,460.52
G _ L _ X . , , ,		
1, 1,	4,193,926,575.18	2,839,595,396.66
	15,738,876,264.18	14,596,698,753.97
the plant of the state of the s	24,211,202,394.34	21,841,695,462.91

Legal Representative: Chen Qiyu

Guan Xiaohui

Chief Financial Officer: Director of the Accounting Department:

Yan Jia

Consolidated Income Statement

January – September 2015



: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

	$^{\prime}$:	□ G Æ ∠:	MB V	7: 7~
Items	Current Amount (July – September)	Amount of the Last Period (July – September)	Current Amount (January – September)	Amount of the Last Period (January – September)
I. I I I I I I	3,152,113,519.72	3,122,905,282.64	9,073,497,568.10	8,661,444,631.29
I 1 . 1: L . 1 & 1	3,152,113,519.72	3,122,905,282.64	9,073,497,568.10	8,661,444,631.29
I \$, , ,				
E_r_ , &, J,				
E				
II.	2,895,782,154.22	2,841,148,358.80	8,300,064,068.03	8,033,810,333.58
I I , I and I	1,549,543,653.59	1,718,871,717.37	4,479,008,803.33	4,905,488,021.73
I J				
F. Man J.				
N . A. A				
Alm Ala	24 407 549 26	22.5(7.921.20	74.510.026.45	50 992 140 42
Bi 1 X 1	24,497,548.36	23,567,831.20	74,510,036.45	59,883,149.42
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	752,785,285.93	589,494,712.71	2,033,469,048.98	1,606,792,320.56
A	439,321,906.97	417,425,034.77	1,340,049,894.95	1,198,838,624.94
F,	118,030,107.88	91,347,934.22	339,686,256.62	251,024,209.33
I : G I I I I I I I I I I I I I I I I I	11,603,651.49	441,128.53	33,340,027.70	11,784,007.60

Consolidated Income Statement (*Continued***)**

January – September 2015

Items	Current Amount (July – September)	Amount of the Last Period (July – September)	Current Amount (January – September)	Amount of the Last Period (January – September)
II. LA	-503,674,636.21	170,383,244.67	-279,141,519.38	146,057,212.28
~ ~ [m/ ~] m/ ~ [m/ ~]	-506,044,279.16	169,738,571.45	-281,896,717.92	147,808,244.36
()				
Î. C				
2. km 1 1 km 1 1 1 km 1 1 1 1 km 1 1 1 1 km 1 1 1 1				
" x 1 " 1 " i" 1, " x ' x	-506,044,279.16	169,738,571.45	-281,896,717.92	147,808,244.36
1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	732,427.55	-9,352.18	-195,739,333.69	-5,108,705.95
2. C 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	-440,970,255.91	171,599,596.74	-16,216,735.14	149,088,050.35
3. G A A A A A A A A A A A A A A A A A A				
4. E = 1 = 1, I				
5. E L L L L L L L L L L L L L L L L L L	-65,806,450.80	-1,851,673.11	-69,940,649.09	3,828,899.96
- 1 bi - 1 bi 1 - 1	2,369,642.95	644,673.22	2,755,198.54	-1,751,032.08
H. A. July J.	157,117,103.71	812,100,177.38	1,897,755,696.77	1,940,074,283.26
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	81,440,708.74	726,766,676.07	1,609,072,739.39	1,722,392,108.74
1 10 1 1 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1	75,676,394.97	85,333,501.31	288,682,957.38	217,682,174.52
III. EA, Lond A:				
(1)	0.25	0.24	0.82	0.69
(2)	0.25	0.24	0.82	0.69

Legal Representative: Chen Qiyu

Chief Financial Officer: Director of the Accounting Department:

Guan Xiaohui

Yan Jia

Consolidated Statement of Cash Flow

January – September 2015



Consolidated Statement of Cash Flow (Continued)

January – September 2015

	Items	Current Amount (January – September)	Amount of the Last Period (January – September)
III.	Cash flow generated from financing activities:		
	C 1 1 1 1	87,721,195.00	1,445,949,451.00
	$I_{\lambda_1,\lambda}:=\lambda_{\lambda_2,\lambda_2}^{\mu_1} , I_{\lambda_1,\lambda_2} \lambda_{\lambda_2,\lambda_3} - \lambda_{\lambda_1,\lambda_2,\lambda_3} .$	87,721,195.00	38,269,850.07
		5,110,056,682.54	3,475,109,758.30
	C 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	398,929,000.00	1,000,000,000.00
		40,140,014.05	21,733,509.09
	1 - Landa Landa Lange	5,636,846,891.59	5,942,792,718.39
	C	3,519,139,442.58	1,623,242,732.68
	C	1,114,614,719.91	1,012,768,967.52
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	268,686,768.21	133,554,721.22
		238,690,425.98	1,512,793,278.03
	1 - Landa American	4,872,444,588.47	4,148,804,978.23
	N Laka Ima Aray	764,402,303.12	1,793,987,740.16
IV.	Effects of exchange rate fluctuations on cash and cash equivalents	5,949,548.99	14,780,312.38
V.	Net increase of cash and cash equivalents		

Statement of Cash Flow of the Parent Company

January – September 2015



Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Items Cash flow generated from operating activities:	Current Amount (January – September)	Amount of the Last Period (January – September)
Cash now generated from operating activities:	450,000.00	450,000.00